United Therapeutics

YTD

ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

CEO

Martine A. Rothblatt

CEOMartine A. Rothblatt

Employees

1,400

Employees1,400

Headquarters

Silver Spring, Maryland

HeadquartersSilver Spring, Maryland

Founded

1996

Founded1996

Employees

1,400

Employees1,400

UTHR Key Statistics

Market cap

25.78B

Market cap25.78B

Price-Earnings ratio

18.76

Price-Earnings ratio18.76

Dividend yield

—

Dividend yield—

Average volume

647.50K

Average volume647.50K

High today

$625.00

High today$625.00

Low today

$549.13

Low today$549.13

Open price

$605.10

Open price$605.10

Volume

1.72M

Volume1.72M

52 Week high

$625.00

52 Week high$625.00

52 Week low

$266.98

52 Week low$266.98

Stock Snapshot

The current United Therapeutics(UTHR) stock price is $587.17, with a market capitalization of 25.78B. The stock trades at a price-to-earnings (P/E) ratio of 18.76.

As of 2026-03-30, United Therapeutics(UTHR) stock has fluctuated between $549.13 and $625.00. The current price stands at $587.17, placing the stock +6.9% above today's low and -6.1% off the high.

United Therapeutics(UTHR) shares are trading with a volume of 1.72M, against a daily average of 647.5K.

In the last year, United Therapeutics(UTHR) shares hit a 52-week high of $625.00 and a 52-week low of $266.98.

UTHR News

TipRanks 11h

What Pushed United Therapeutics Stock Higher Today?

United Therapeutics (UTHR) stock was on the rise Monday after the biotechnology company announced results from its TETON-1 and TETON-2 studies of Tyvaso. These...

TipRanks 12h

United Therapeutics’ Tyvaso Shows Pivotal Success in IPF

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 13h

United Therapeutics announces TETON-1 study met primary efficacy endpoint

United Therapeutics (UTHR) announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis met its pr...

Analyst ratings

75%

of 16 ratings

Buy

75%

Hold

25%

Sell

More UTHR News

Investing.com 4d

Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock - Investing.com

...

Simply Wall St 6d

Assessing United Therapeutics Valuation As Organ Programs Shape Its 2026 Narrative

Advertisement Why United Therapeutics Is On Investors’ Radar United Therapeutics (UTHR) is drawing attention after a recent move in its share price, with the...

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.